RXRX Stock Price Today (October 2026) — Recursion Pharmaceuticals, Inc. Analysis & Key Metrics 2026-10-08
Recursion Pharmaceuticals, Inc. (RXRX) is trading at $3.95, down 7.49% today (as of October 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $7.22 (82.8% upside).
- Volatility is high (87.67% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: declining revenue trends (-60.10% YoY) alongside competitive pressures in the Biotechnology space.
RXRX Stock Analysis: Key Metrics & Valuation (October 2026)
Concise, actionable data for investors
Recursion Pharmaceuticals, Inc. - Historical Price & Volume
- Price
- Volume
- Latest price
Market Cap
Enterprise Value: $1.64B
P/E Ratio
Forward P/E: N/A
Revenue Growth
Year over Year
Analyst Target
+82.8% upside potential
Key Investor Questions About RXRX
What investors need to know before buying
Based on current market data, RXRX presents a neutral technical setup with challenging fundamentals.
- Technicals say: Neutral (RSI 50.34)
- Fundamentals say: Challenging (declining revenue trends)
RXRX's growth trajectory depends on its ability to expand within the Biotechnology sector while managing margin pressures.
- Future growth will depend on performance in core Biotechnology operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for RXRX investors include debt exposure and competitive dynamics in the Biotechnology industry.
- $66.64M in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Biotechnology.
52-Week Trading Range
Over the past year, RXRX stock traded between $2.77 and $7.18 and currently trades in the middle of that range. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 87.67% annualized volatility and β=3.13, the stock exhibits high sensitivity to market moves—making RXRX suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth?
RXRX's strategic partnerships are expanding its drug pipeline, strengthening AI capabilities and providing non-dilutive funding through early 2028.
Recursion Pharmaceuticals (RXRX) Stock Moves 2.02%: What You Should Know
The latest trading day saw Recursion Pharmaceuticals (RXRX) settling at $4.05, representing a +2.02% change from its previous close.
Recursion Pharmaceuticals Highlights AI Drug Platform, FAP Progress at Morgan Stanley Conference
Recursion Pharmaceuticals (NASDAQ:RXRX) outlined its strategy, clinical pipeline and partnership progress at Morgan Stanley’s Global Healthcare Conference, with CEO and President Najat Khan emphasizing the company’s shift toward an end-to-end, AI-enabled drug discovery and development platform. Kha
Is Recursion Pharmaceuticals (RXRX) A Bargain As Its Shares Rebound?
Recursion Pharmaceuticals (RXRX) is back on traders’ screens after a sharp daily move, with the share price closing at US$3.83. Recent returns have been mixed over the past week and month. For context, Recursion Pharmaceuticals has delivered an 8.19% 1-day share price return and a 19.69% 7-day share price return, yet the total shareholder return over the past year is down 22%. This hints at short-term momentum building against a more difficult long-term backdrop and shifting views on the...
Recursion Pharmaceuticals (RXRX) Falls More Steeply Than Broader Market: What Investors Need to Know
In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $3.18, marking a -1.85% move from the previous day.
Why Recursion Pharmaceuticals (RXRX) Dipped More Than Broader Market Today
Recursion Pharmaceuticals (RXRX) concluded the recent trading session at $3.16, signifying a -1.71% move from its prior day's close.
Why Is Recursion Pharmaceuticals (RXRX) Up 8.2% Since Last Earnings Report?
Recursion Pharmaceuticals (RXRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Can RXRX's Pipeline Expansion Strengthen Its Long-Term Growth Outlook?
Recursion Pharmaceuticals is expanding its clinical pipeline across oncology and rare diseases, with REC-4881 and multiple programs offering potential growth catalysts.
The Zacks Analyst Blog Highlights Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics and Absci
AI is reshaping drug discovery, with Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics and Absci advancing computational platforms and pipelines.
Explore More Analysis for RXRX
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Earnings snapshot
Next report Nov 3, 2026 (before the open, usually)
Frequently Asked Questions
Common investor questions about Recursion Pharmaceuticals, Inc.
Recursion Pharmaceuticals, Inc. (RXRX) is currently trading at $3.95. The RSI (14-day) is at 50.3, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $7.22 implies 82.8% upside from current levels. Volatility is high at 87.7% annualized, meaning significant price swings are common. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Recursion Pharmaceuticals, Inc. (RXRX): The trailing P/E ratio is not available (the company may not be profitable). Price-to-Book is 1.99. Price-to-Sales is 33.28. Valuation should be compared to Biotechnology industry peers for context, as different sectors trade at different multiples.
Based on 6 analysts covering RXRX, the consensus price target is $7.22. This represents a 82.8% upside from the current price of $3.95. The range spans from a low target of $4.00 to a high target of $10.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Recursion Pharmaceuticals, Inc. (RXRX) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Recursion Pharmaceuticals, Inc. (RXRX) investors include: 1. High volatility (87.7% annualized)—the stock can experience significant daily price swings. 2. The company is not currently profitable on a trailing basis, which creates earnings uncertainty. 3. Declining revenue (-60.1% YoY), indicating potential business headwinds. 4. Elevated short interest (35.0% of float) suggests significant bearish sentiment. 5. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 6. Biotechnology sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Recursion Pharmaceuticals, Inc.'s (RXRX) current debt and financial health profile: Total debt stands at $66.64M. The debt-to-equity ratio is 0.07x, which is conservative and indicates a strong balance sheet with low leverage. The current ratio is 5.03, indicating strong short-term liquidity. The quick ratio is 4.67. The company holds $545.68M in cash and equivalents. Free cash flow is negative at -$219.49M, which could limit the company's ability to manage debt obligations.